Literature DB >> 6789494

Inhibition of human platelet functions by verapamil.

Y Ikeda, M Kikuchi, K Toyama, K Watanabe, Y Ando.   

Abstract

The effects of verapamil, a coronary vasodilator, on platelet functions was studied. Platelet aggregation induced by ADP, epinephrine or collagen was inhibited by verapamil in vitro. Calcium ionophore A23187-induced platelet aggregation was also inhibited by verapamil in a concentration dependent manner. In washed platelets, verapamil caused a dose-dependent inhibition of serotonin release induced either by thrombin or A23187 in the absence of extracellular calcium. Addition of 1 mM CaCl2 with A23187 or thrombin partially overcame this inhibition. Addition of 1 mM CaCl2 in the absence of verapamil had no effect on thrombin- or A23187-induced secretion. When verapamil was administered to the healthy volunteers at the dosage commonly used, inhibition of platelet aggregation was observed 2 hrs after the drug ingestion. It is of great interest that verapamil potentiated the anti-aggregating activity of prostacyclin in vitro. Our results may suggest a potential role for verapamil in the treatment of thrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6789494

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Epinephrine at doses used in dentistry deteriorates platelet retention rate.

Authors:  T Ichinohe; K Fukuda; Y Kaneko
Journal:  Anesth Prog       Date:  1997

2.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

3.  The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.

Authors:  J L Francis; O S Roath; V F Challenor; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

4.  Proceedings of the British Pharmacological Society 8th-10th September, 1982. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1982-12       Impact factor: 8.739

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 6.  Protective effects of calcium antagonists against ischaemia and reperfusion damage.

Authors:  R Ferrari; O Visioli
Journal:  Drugs       Date:  1991       Impact factor: 9.546

7.  The influence of cyclandelate on Ca++ translocation in human platelets.

Authors:  J W Akkerman; W E van den Hoven
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

9.  Inhibition of human platelet functions by cyclandelate.

Authors:  W E van den Hoven; D W Hall
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Stereospecific inhibition of 5-HT-induced increase of intracellular free calcium by (+)- and (-)-desmethoxyverapamil in human platelets.

Authors:  C Bruns; D Marmé; H Osswald
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.